KINE-101A is under clinical development by Kine Sciences and currently in Phase I for Rheumatoid Arthritis. According to GlobalData, Phase I drugs for Rheumatoid Arthritis have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KINE-101A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KINE-101A overview

KINE-101A is under development for the treatment of rheumatoid arthritis. The drug is derived from erythroid differentiation regulator 1 (Erdr1). It is administered through oral route. The drug candidate is a ERDR1 derivative.

Kine Sciences overview

Kine Sciences (KS) is a Korean based pharmaceutical manufacturing company. The company is engaged in the manufacture of drugs for unmet medical and patient needs. It primarily focuses in developing drugs across various therapeutic areas including cancer, skin diseases, autoimmune disease and cardiovascular disease. It is company that develops ultra-small peptide innovative medicines based on functional immunomics. The company is involved in developing drug candidates of ultra-small peptide with private and public funding including the one from Korea Drug Development Fund. The diseases it aims to treat are chronic immune diseases such as rheumatoid arthritis, inflammatory bowel diseases, atopic dermatitis, psoriasis, cancer, Alzheimer’s disease, and many rare immune diseases. Kine Sciences is headquartered in Gangnam, Seoul, South Korea.

For a complete picture of KINE-101A’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.